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Background
BRIM7 is a phase 1B study evaluating the safety and effi-
cacy of combined BRAF and MEK inhibition with vemura-
fenib + cobimetinib. The utility of FDG-PET as an early
predictor of clinical benefit was also evaluated in this study.
Materials and methods
Eligible patients (pts) had advanced BRAFV600-mutated
melanoma and ECOG PS 0-1 and were either naïve to
BRAF inhibitor (BRAFi-naïve) or had disease progression
on vemurafenib (vem-progressor). Pts in the dose-escala-
tion portion received vemurafenib 720 or 960 mg BID
continuously and cobimetinib 60, 80, or 100 mg QD
14 days (d) on/14 d off (14/14); 21 d on/7 d off (21/7); or
continuously (28/0). Two dose levels were expanded:
vemurafenib (720 mg and 960 mg BID) + cobimetinib
60 mg QD 21/7. FDG-PET scans were performed at base-
line and on Day 15 of Cycles 1 and 2. Correlation between
tumor glucose metabolism changes, baseline tumor
burden and target lesion responses were evaluated.
Results
128 pts were treated with vemurafenib + cobimetinib as of
21 June 2013; male 60%, median age 55 y (19-88), stage
M1c 76% and BRAFi-naive 49%. Median duration of fol-
low-up in vem-progressor and BRAFi-naïve pts was 3 and
10 months, respectively. Most adverse events (AE) were
mild to moderate in severity and vem-progressor pts
reported fewer AEs compared to BRAFi-naïve pts. Most
common AEs in BRAFi-naïve pts (n=63) were non-acnei-
form rash (89%), diarrhea (81%), photosensitivity/sunburn
(70%), fatigue (67%) and liver test abnormality (59%).
Most frequent grade ≥3 AEs in BRAFi-naïve pts were liver
test abnormality (19%), non-acneiform rash (13%), arthral-
gia (11%) and fatigue (10%).
BRAFi-naive pts attained 85% confirmed response rate
(RR), including 10% complete responses; median PFS was
not reached at 10 months follow-up. Vem-progressor pts
attained 15% confirmed RR, stable disease of 43%, and
median PFS of 2.8 months. Preliminary FDG-PET analysis
showed that the magnitude of reduction in tumor glucose
uptake correlated with maximal tumor reduction, but the
degree of correlation varied across time and in BRAFi-
naïve and Vem-progressor pts.
Conclusions
Vemurafenib + cobimetinib can be safely administered at
the respective single-agent MTDs of vemurafenib (960 mg
BID) and cobimetinib (60 mg 21/7). Preliminary efficacy
of the combination is encouraging in BRAFi-naive
patients. FDG-PET is a potentially useful marker of early
biologic response to the combination.
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